Back to Journals » Drug Design, Development and Therapy » Volume 7

Antituberculosis nanodelivery system with controlled-release properties based on para-amino salicylate–zinc aluminum-layered double-hydroxide nanocomposites

Authors Saifullah B, Hussein MZ, Hussein-Al-Ali SH, Arulselvan P, Fakurazi S

Received 28 June 2013

Accepted for publication 27 August 2013

Published 13 November 2013 Volume 2013:7 Pages 1365—1375

DOI https://doi.org/10.2147/DDDT.S50665

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Bullo Saifullah,1 Mohd Zobir Hussein,1 Samer Hasan Hussein-Al-Ali,2 Palanisamy Arulselvan,3 Sharida Fakurazi3,4

1Materials Synthesis and Characterization Laboratory, 2Laboratory of Molecular Biomedicine, 3Laboratory of Vaccines and Immunotherapeutics, 4Department of Human Anatomy, Universiti Putra Malaysia, Serdang, Selangor, Malaysia

Abstract: We report the intercalation and characterization of para-amino salicylic acid (PASA) into zinc/aluminum-layered double hydroxides (ZLDHs) by two methods, direct and indirect, to form nanocomposites: PASA nanocomposite prepared by a direct method (PASA-D) and PASA nanocomposite prepared by an indirect method (PASA-I). Powder X-ray diffraction, Fourier-transform infrared spectroscopy, and thermogravimetric analysis revealed that the PASA drugs were accommodated within the ZLDH interlayers. The anions of the drug were accommodated as an alternate monolayer (along the long-axis orientation) between ZLDH interlayers. Drug loading was estimated to be 22.8% and 16.6% for PASA-D and PASA-I, respectively. The in vitro release properties of the drug were investigated in physiological simulated phosphate-buffered saline solution of pH 7.4 and 4.8. The release followed the pseudo-second-order model for both nanocomposites. Cell viability (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide [MTT] assays) was assessed against normal human lung fibroblast MRC-5 and 3T3 mouse fibroblast cells at 24, 48, and 72 hours. The results showed that the nanocomposite formulations did not possess any cytotoxicity, at least up to 72 hours.

Keywords: drug-delivery system, slow-release nanocarrier, tuberculosis, biocompatible nanocomposites

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]